Fast Growing Stocks With High Insider Ownership

Results

185

25 new

Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.

185 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
	PGEN	US$6.10	-12.9%	106.8%	US$2.2b	US$14.50	25.5	55.4%	n/a	Pharmaceuticals & Biotech
	ALM	US$15.09	10.1%	222.4%	US$4.4b	US$25.28	56.2	37.1%	n/a	Materials
	HIMX	US$15.23	3.4%	100.7%	US$2.7b	US$30.20	75.3	70.2%	2.4%	Semiconductors
	DAVE	US$334.57	8.3%	65.4%	US$4.3b	US$429.91	19.2	22.8%	n/a	Diversified Financials
	ALAB New	US$321.61	1.4%	72.5%	US$55.8b	US$391.77	151.0	33.2%	n/a	Semiconductors
	UPST	US$30.43	0.7%	-53.4%	US$3.0b	US$40.60	49.1	66.5%	n/a	Diversified Financials
	KRMN	US$62.01	-0.2%	19.8%	US$8.2b	US$87.10	221.0	54.0%	n/a	Capital Goods
	APP	US$315.44	-6.9%	-28.1%	US$105.6b	US$548.52	23.9	20.6%	n/a	Media
	UXIN	US$1.18	0.9%	-67.5%	US$259.6m	US$4.00	0.5	69.4%	n/a	Retail
	CG	US$49.28	3.1%	-22.3%	US$17.6b	US$58.06	48.3	20.5%	2.8%	Diversified Financials
	HNGE	US$88.49	-3.4%	49.9%	US$7.1b	US$106.47	66.6	27.1%	n/a	Healthcare
	EROC	US$16.72	59.1%	n/a	US$4.6b	US$22.88	5.0	57.9%	0%	Capital Goods
	IREN	US$44.06	13.7%	112.8%	US$15.7b	US$81.73	99.6	40.2%	n/a	Software
	TEM	US$52.10	-5.4%	-33.6%	US$9.4b	US$62.64	6.6	45.0%	n/a	Pharmaceuticals & Biotech
	CORT	US$114.47	0.2%	59.5%	US$12.4b	US$135.25	228.0	44.8%	n/a	Pharmaceuticals & Biotech
	WULF New	US$17.38	7.3%	85.3%	US$8.7b	US$36.64	52.5	99.1%	n/a	Software
	HSAI	US$18.21	-5.6%	-31.6%	US$2.8b	US$29.65	40.7	27.4%	n/a	Automobiles
	EH	US$5.93	4.2%	-66.7%	US$449.8m	US$11.42	7.3	69.1%	n/a	Capital Goods
	ABEO	US$5.99	-19.7%	-13.4%	US$342.2m	US$18.86	13.4	70.2%	n/a	Pharmaceuticals & Biotech
	MUX New	US$18.80	-2.0%	78.0%	US$1.2b	US$31.00	14.3	58.8%	0%	Materials
	ALOY	US$14.72	13.4%	117.1%	US$1.0b	US$17.00	543.0	80.6%	n/a	Materials
	PGY	US$21.56	1.3%	-35.3%	US$1.8b	US$28.80	14.7	36.1%	n/a	Software
	ZS	US$183.60	3.9%	-33.7%	US$29.7b	US$192.77	9.4	47.4%	n/a	Software
	XCH New	US$0.26	-7.6%	-77.8%	US$22.6m	n/a	0.9	102.2%	n/a	Capital Goods

Page 1 of 6